Clinical Trial Update: flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating flt3L with or without vaccine therapy in patients with metastatic melanoma or renal cell cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Cancer

Drugs mentioned

• Flt3L (FLT3 ligand)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IV Melanoma, Stage IV Renal Cell Cancer | Phase 2 | Status: COMPLETED